Imunon, Inc.

Equities

IMNN

US15117N6022

Biotechnology & Medical Research

Delayed Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
1.4 USD +19.75% Intraday chart for Imunon, Inc. +79.49% +105.88%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Stocks Set for -2- DJ
Imunon, Inc. Files Ind Application to Begin Human Testing of Imnn-101 CI
IMUNON Names Executive Chairman as Temporary Head Following Resignation of CEO Corinne Le Goff MT
Imunon, Inc. Announces Executive Changes CI
Imunon, Inc. Announces Resignation of Corinne Le Goff as Chief Executive Officer, Effective March 15, 2024 CI
Imunon, Inc. Appoints Sebastien Hazard as Executive Vice President and Chief Medical Officer CI
Transcript : Imunon, Inc., Q3 2023 Earnings Call, Nov 14, 2023
Imunon, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Imunon, Inc. Provides an Update on Its Clinical Development Programs with Imnn-001 (Formerly Gen-1), A Dna-Based Interleukin-12 (Il-12) Immunotherapy in Phase 2 Clinical Development for the Treatment of First-Line Locally Advanced Ovarian Cancer CI
IMUNON, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of IMUNON-001 in Combination with Bevacizumab in Advanced Ovarian Cancer CI
Imunon, Inc. Appoints Patrick Ott to Its Scientific Advisory Board CI
Transcript : Imunon, Inc. - Special Call
Imunon Strikes Deal For Preclinical Studies in Vaccines Against Lassa Virus MT
Imunon, Inc. Appoints Sachet A. Shukla to Its Scientific Advisory Board CI
Transcript : Imunon, Inc., Q2 2023 Earnings Call, Aug 10, 2023
Imunon, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
IMUNON, Inc. Announces Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv CI
Imunon Opening New Manufacturing Facility in Alabama to Support Production of Vaccine Formulation Components MT
IMUNON, Inc. Unveils New Manufacturing Capabilities at Huntsville's HudsonAlpha Biotech Campus CI
Imunon, Inc. Announces the Retirement of Augustine Chow as Class I Member of the Board of Directors CI
Transcript : Imunon, Inc., Q1 2023 Earnings Call, May 11, 2023
Imunon, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Transcript : Imunon, Inc., 2022 Earnings Call, Mar 30, 2023
Imunon, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
North American Morning Briefing : Stocks Seen -2- DJ
Chart Imunon, Inc.
More charts
Imunon, Inc. is a clinical-stage biotechnology company. It is focused on advancing a portfolio of treatments that harness the body's natural mechanisms across an array of human diseases. It has two platform technologies: TheraPlas platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies, and the PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. Its lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer. IMNN-001 works by instructing the body to produce cancer fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, it is conducting preclinical studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus to validate its PLACCINE platform. Its platform technologies are based on the delivery of nucleic acids with synthetic delivery systems that are independent of viral vectors or devices.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.4 USD
Average target price
11.67 USD
Spread / Average Target
+733.33%
Consensus
  1. Stock
  2. Equities
  3. Stock Imunon, Inc. - Nasdaq
  4. News Imunon, Inc.
  5. Celsion : Shares Soar Pre-Bell as FDA Grants Fast-Track Status to Gen-1 to Treat Ovarian Cancer